Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

IF 2.5 4区 医学 Q3 CHEMISTRY, MEDICINAL
Taiji Goto , Akiko Shiina , Toshiharu Yoshino , Kiyoshi Mizukami , Kazuki Hirahara , Osamu Suzuki , Yoshitaka Sogawa , Tomoko Takahashi , Tsuyoshi Mikkaichi , Naoki Nakao , Mizuki Takahashi , Masashi Hasegawa , Shigeki Sasaki
{"title":"Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors","authors":"Taiji Goto ,&nbsp;Akiko Shiina ,&nbsp;Toshiharu Yoshino ,&nbsp;Kiyoshi Mizukami ,&nbsp;Kazuki Hirahara ,&nbsp;Osamu Suzuki ,&nbsp;Yoshitaka Sogawa ,&nbsp;Tomoko Takahashi ,&nbsp;Tsuyoshi Mikkaichi ,&nbsp;Naoki Nakao ,&nbsp;Mizuki Takahashi ,&nbsp;Masashi Hasegawa ,&nbsp;Shigeki Sasaki","doi":"10.1016/j.bmcl.2013.03.104","DOIUrl":null,"url":null,"abstract":"<div><p>2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-<em>d</em>]pyrimidine derivative (<strong>2</strong><span><span>) was found to be a new PDE4 inhibitor with moderate </span>PDE4B activity (IC</span><sub>50</sub> <!-->=<!--> <!-->150<!--> <!-->nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-<em>d</em>]pyrimidine derivative (<strong>18</strong>) showed potent PDE4B inhibitory activity (IC<sub>50</sub> <!-->=<!--> <!-->25 nM). Finally, <em>N</em>-propylacetamide derivative (<strong>31b</strong>) was determined as a potent inhibitor for both PDE4B (IC<sub>50</sub> <!-->=<!--> <!-->7.5<!--> <span>nM) and TNF-α production in mouse splenocytes (IC</span><sub>50</sub> <!-->=<!--> <!-->9.8<!--> <!-->nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID<sub>50</sub> <!-->=<!--> <!-->18<!--> <!-->mg/kg). The binding mode of the new inhibitor (<strong>31e</strong>) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand–enzyme complex.</p></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"23 11","pages":"Pages 3325-3328"},"PeriodicalIF":2.5000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bmcl.2013.03.104","citationCount":"32","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X13004320","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 32

Abstract

2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC50 = 150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50 = 25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50 = 7.5 nM) and TNF-α production in mouse splenocytes (IC50 = 9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50 = 18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand–enzyme complex.

Abstract Image

融合双环4-氨基-2-苯基嘧啶衍生物作为新型有效的PDE4抑制剂的鉴定
2-苯基-4-哌啶基-6,7-二氢噻吩[3,4-d]嘧啶衍生物(2)是一种新的PDE4抑制剂,具有中等的PDE4B活性(IC50 = 150 nM)。合成了一系列具有不同4-氨基取代基和融合双环嘧啶的衍生物。其中,5,5-二氧基-7,8-二氢- 6h -硫代吡喃[3,2-d]嘧啶衍生物(18)表现出较强的PDE4B抑制活性(IC50 = 25 nM)。最后,n -丙基乙酰胺衍生物(31b)对小鼠脾细胞产生PDE4B (IC50 = 7.5 nM)和TNF-α (IC50 = 9.8 nM)均有抑制作用,并在lps诱导的小鼠肺炎症模型(ID50 = 18 mg/kg)中表现出良好的体内抗炎活性。基于配体-酶配合物的x射线晶体结构,给出了新型抑制剂(31e)在PDE4B催化位点的结合模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
3.70%
发文量
463
审稿时长
27 days
期刊介绍: Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信